Article

Limbal deficiency more common than realized

Limbal stem cell deficiency is more common than often recognized, said Edward Holland, MD, director of Cornea Service at the Cincinnati Eye Institute and professor at the University of Cincinnati in Cincinnati.

San Francisco-Limbal stem cell deficiency is more common than often recognized.

Contact lens wear, eye drops for glaucoma, treatment with mitomycin C, thermal trauma, and a variety of common events can cause limbal cell deficiency, said Edward Holland, MD, director of Cornea Service at the Cincinnati Eye Institute and professor at the University of Cincinnati in Cincinnati. One of the most important causes is clinicians who perform keratoplasty in an attempt to deal with complications of limbal stem cell loss.

“Patients with limbal deficiencies will not do well with keratoplasty,” Dr. Holland said.

“Even if you don’t treat patients with limbal cell deficiency, you need to be aware of the problem,” he said. “If you are following patients with contact lenses, dry eye, or long-term glaucoma meds, you need to think about your treatment and possibly changing it to deal with the problem.”

Patients with glaucoma, for example, can develop limbal stem cell deficiency from long-term use of eye drops. The solution: early intervention with shunts or other devices to reduce medication use. Patients who wear contact lenses may need to change lens types or avoid contacts altogether.

Other causes of limbal stem cell deficiency include inflammatory conditions, such as Stevens-Johnson syndrome or mucous membrane pemphigoid, or congenital conditions, such as aniridia. Whatever the cause, patients with limbal stem cell deficiency have persistent epithelial defects, corneal scarring and ulceration, conjunctivalization of the cornea, severe visual loss, and chronic pain.

In addition to reducing avoidable causes such as contact lens trauma, clinicians should consider both medical and surgical treatments. Medical options for mild limbal stem cell deficiency include preservative-free lubricants, bandage contact lenses or scleral contact lenses, topical steroids, topical vitamin A ointment, and autologous serum drops.

“Patients have options for visual recovery,” Dr. Holland said. “As clinicians, we need to recognize the early clinical signs of limbal stem cell deficiency and stop progression.”

For more articles in this issue of Ophthalmology Times Conference Brief, click here.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.